Covishield current monthly production capacity 250-275 million doses, Covaxin 50-60 million doses, says Government Read more
FDA expands authorisation of two monoclonal antibodies for treatment and post-exposure prevention of COVID-19 to paediatric patients Read more
SPARC enters into licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target Read more